Relay Therapeutics Q1 2026 Earnings Report

Relay Therapeutics EPS Results

• Actual EPS: -$0.41
• Consensus EPS: -$0.35
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Relay Therapeutics Revenue Results

• Actual Revenue: $3.00 million
• Expected Revenue: $5.58 million
• Beat/Miss: Missed by -$2.58 million
• YoY Revenue Growth: N/A

Relay Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/5/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, May 5, 2026
• Conference Call Time: 4:00PM ET

Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This approach enables Relay to explore conformational changes in proteins that have historically been difficult to target, opening new avenues for therapeutic intervention. Relay’s pipeline comprises multiple preclinical and clinical programs aimed at oncogenic drivers implicated in a range of solid tumors.

Relay Therapeutics has progressed a number of assets into human trials, with initial studies evaluating safety, tolerability and preliminary signs of clinical activity. In addition to its internal development programs, the company collaborates with academic institutions and other biopharmaceutical companies to expand the application of its platform across diverse therapeutic areas. Relay’s research efforts are supported by partnerships that bring complementary expertise and resources to accelerate the identification of novel drug candidates.

Under the leadership of President and Chief Executive Officer Michael Gilman, Ph.D., Relay Therapeutics continues to advance its vision of precision oncology medicines that address unmet medical needs. The company’s operations are primarily based in the United States, while its clinical trials enroll patients across North America and select international sites. Relay Therapeutics is publicly traded on the Nasdaq under the ticker symbol RLAY.